2-氯-5-硝基苯甲酸 | 2516-96-3

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-5-硝基苯甲酸
• 中文别名: 5-硝基邻氯苯甲酸；美沙拉嗪杂质M
• 英文名称: 2-chloro-5-nitrobenzoic acid
• 英文别名: 5-nitro-2-chlorobenzoic acid；2-carboxy-4-nitro-chlorobenzene
• CAS: 2516-96-3
• 化学式: C₇H₄ClNO₄
• mdl: MFCD00007294
• 分子量: 201.566
• InChiKey: QUEKGYQTRJVEQC-UHFFFAOYSA-N

物化性质

• 熔点：
  165-168 °C (lit.)
• 沸点：
  356.5±27.0 °C(Predicted)
• 密度：
  1.6
• 闪点：
  >100°C
• 溶解度：
  3.6克/升
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 安全说明：
  S24/25,S26,S39,S61
• 危险类别码：
  R36/37/38
• WGK Germany：
  1
• 海关编码：
  2916399090
• 危险品运输编号：
  UN3077 9/PG 3
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将容器密封，并将其存放在紧密封装的储存器中。应将其储存在阴凉、干燥的地方。

SDS

Name:	2-Chloro-5-nitrobenzoic acid 99+%(gc) Material Safety Data Sheet
Synonym:
CAS:	2516-96-3

Section 1 - Chemical Product MSDS Name:2-Chloro-5-nitrobenzoic acid 99+%(gc) Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2516-96-3	2-Chloro-5-nitrobenzoic acid	99+(GC)	219-739-7

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2516-96-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: off-white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 166.00 - 168.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water: insoluble
Specific Gravity/Density:
Molecular Formula: C7H4ClNO4
Molecular Weight: 201.57

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2516-96-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Chloro-5-nitrobenzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2516-96-3: 1
Canada
CAS# 2516-96-3 is listed on Canada's NDSL List.
CAS# 2516-96-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2516-96-3 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

现有技术中制备2-氯-5-硝基苯甲酸的方法是采用邻氯苯甲酸进行硝化后再精制。但由于在硝化过程中会生成较多的2-氯-3-硝基苯甲酸异构体，常规的精制方法难以达到高纯度，一般只能控制在99.0%左右，无法满足使用需求。

应用

2-氯-5-硝基苯甲酸常温常压下为浅黄色至米色棕色固体粉末状，可用作有机合成和医药化学中间体，在农药分子和生物活性分子的制备以及精细化工生产中有着较为广泛的应用。

化学性质

从水中析出针状结晶。熔点在165-166℃（有时范围为166-168℃），相对密度1.608（温度条件为18/4℃）。它溶于乙醇、乙醚和苯，微溶于冷水。

用途

2-氯-5-硝基苯甲酸主要用于合成2-氯-5-氨基苯甲酸、5-硝基水杨酸及其酯类和酰胺类中间体。此外，它还可作为农药、医药以及有机颜料的中间体。

生产方法

由邻氯苯甲酸经硝化而得。具体步骤为：将邻氯苯甲酸与硫酸冷却至0℃以下后，加入混酸，在0℃下进行硝化反应8小时，随后加热至60℃，再倒入冰水中析出硝基物，并通过重结晶得到成品。

反应信息

• 作为反应物：
  描述：

  2-氯-5-硝基苯甲酸 在 硫酸 、 potassium phenolate 、 硝酸 、 铜 作用下， 生成 5-硝基-2-(4-硝基-苯氧基)-苯甲酸
  参考文献：
  名称：

  Iodo Derivatives of Diphenyl Ether. I. The Mono- and Certain Diiodo-Derivatives of Diphenyl Ether, and of 2- and 4-Carboxy Diphenyl Ethers¹

  摘要：

  DOI：

  10.1021/ja01316a035
• 作为产物：
  描述：

  2-氯苯甲酸 在 硫酸 、 potassium nitrate 作用下， 反应 3.0h， 以90.2%的产率得到2-氯-5-硝基苯甲酸
  参考文献：
  名称：

  设计，合成和生物学评估作为拓扑异构酶I抑制剂的3-取代的茚并异喹啉衍生物

  摘要：

  设计并合成了一系列新的茚并异喹啉衍生物。在HepG2，A549和HCT-116细胞系中评估了这些新型化合物的体外抗增殖活性。化合物9a，9b，10a，10c，10e，18a和18b表现出对三种测试癌细胞系的有效抑制活性。还测试了19种化合物在50μM下对Top I的抑制作用。在该浓度下，几乎所有测试的化合物都显示出有效的Top I抑制活性。最有效的化合物9a和10a 与HCPT和TPT相比，它具有更高的细胞毒性，并且在我们的生物学分析中，对Top I的抑制活性可与CPT相媲美。

  DOI：

  10.1016/j.bmcl.2015.12.014

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• 3-Alkoxy-thianapthene-2-carboxamides
  申请人：Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France

  公开号：US03954748A1

  公开（公告）日：1976-05-04

  The 3-alkoxy-thianaphthene-2-carboxamides of this invention are effective for the treatment of mammals afflicted with emesis. When administered to dogs in dosages of 250 .mu.g/kg, compounds of this invention give 100% protection against vomiting normally induced by subcutaneous administration of apomorphine. The compounds of this invention also favorably modify behavior disturbances in mammals.

  这项发明的3-烷氧基噻吩并2-羧酰胺对患有呕吐症的哺乳动物有效。当以250微克/千克的剂量给狗服用时，这项发明的化合物可使狗免受皮下注射阿波莫啡引起的呕吐，保护效果达到100%。这项发明的化合物还有助于改善哺乳动物的行为紊乱。
• Thioimides: New Reagents for Effective Synthesis of Thiolesters from Carboxylic Acids
  作者：Adam Henke、Jiri Srogl

  DOI：10.1021/jo801319x

  日期：2008.10.3

  carboxylic acids are used as the precursors for the convenient synthesis of thiolesters in the phosphine mediated process. Cyclic and acyclic thioimides show equal efficiency, furnishing the desired thiolesters in good to excellent yields. The general, highly efficient transformation tolerates various functional groups and the resulting thiolesters are obtained in high purity after a simple separation. The

  硫代酰亚胺和羧酸用作在膦介导的过程中方便合成硫酯的前体。环状和无环硫代酰亚胺显示出相同的效率，以良好或优异的收率提供了所需的硫酯。一般的高效转化耐受各种官能团，并且在简单分离后以高纯度获得所得的硫代酯。反应范围已在几种高度官能化的目标分子的制备中得到证明。
• Inhibitory growth evaluation and apoptosis induction in MCF-7 cancer cells by new 5-aryl-2-butylthio-1,3,4-oxadiazole derivatives
  作者：Rashmin Khanam、Kamal Ahmad、Iram I. Hejazi、Ibrar A. Siddique、Vikash Kumar、Abdul Roouf Bhat、Amir Azam、Fareeda Athar

  DOI：10.1007/s00280-017-3414-6

  日期：2017.11

  regulation of apoptotic signaling pathways may lead to cancer formation. Subsequently, the synthesis of effective chemotherapeutic agents that can induce apoptosis in tumor cell has emerged as a significant approach in cancer drug discovery. METHODS The goal of this work is to develop a potential antitumor agent exerting significant inhibitory effects on cancer cell and low cytotoxicity, for which we focused

  背景技术癌症已经成为全球健康问题之一，并且它是威胁生命的疾病，其特征在于细胞不受限制地生长。尽管化学疗法的管理取得了各种进步，但是由于高毒性，副作用和发展的耐药性，目前的抗癌药物如阿霉素，天冬酰胺酶，甲氨蝶呤，长春新碱的使用仍然受到限制。凋亡是关键的细胞过程，凋亡信号通路的调控不当可能导致癌症形成。随后，可以在肿瘤细胞中诱导凋亡的有效化学治疗剂的合成已成为癌症药物发现中的重要方法。方法这项工作的目的是开发一种潜在的抗肿瘤药物，该药物对癌细胞具有显着的抑制作用，且细胞毒性低，为此，我们将重点放在1,3,4-恶二唑的结构特征上，因为它是现代药物化学中的优先支架，并具有抑制可能与实现细胞永生和致癌作用有关的生长因子，酶和激酶的能力。结果体外MTT筛选试验显示化合物5-氨基苯基-2-丁基硫代-1,3,4-恶二唑（5e）对MCF-7癌细胞表现出最高的抑制作用，IC50值为10.05±1.08 µM，
• Tricyclic benzazepine vasopressin antagonists
  申请人：American Cyanamid Company

  公开号：US05532235A1

  公开（公告）日：1996-07-02

  Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.

  通用式I的三环化合物：##STR1##，如本文所定义，在V.sub.1和/或V.sub.2受体表现出拮抗活性，并在体内表现出抗利尿素拮抗活性，使用这类化合物治疗以肾脏过度重吸水为特征的疾病的方法，以及制备这类化合物的方法。

表征谱图